JP2013523843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523843A5 JP2013523843A5 JP2013504061A JP2013504061A JP2013523843A5 JP 2013523843 A5 JP2013523843 A5 JP 2013523843A5 JP 2013504061 A JP2013504061 A JP 2013504061A JP 2013504061 A JP2013504061 A JP 2013504061A JP 2013523843 A5 JP2013523843 A5 JP 2013523843A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- cancer
- antibody
- drug according
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100015206 VEGFC Human genes 0.000 claims 14
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 14
- 108090001123 antibodies Proteins 0.000 claims 12
- 102000004965 antibodies Human genes 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 229940079593 drugs Drugs 0.000 claims 9
- 230000003042 antagnostic Effects 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 102100015249 VEGFA Human genes 0.000 claims 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 210000004408 Hybridomas Anatomy 0.000 claims 3
- 210000003932 Urinary Bladder Anatomy 0.000 claims 3
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims 3
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 3
- 230000000259 anti-tumor Effects 0.000 claims 3
- 239000000890 drug combination Substances 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 229960002949 Fluorouracil Drugs 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 230000000118 anti-eoplastic Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000000306 recurrent Effects 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- 229920002395 Aptamer Polymers 0.000 claims 1
- 108010005144 Bevacizumab Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 210000004907 Glands Anatomy 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000000903 blocking Effects 0.000 claims 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 229940000425 combination drugs Drugs 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 230000002485 urinary Effects 0.000 claims 1
Claims (14)
- 治療に有効な量のVEGF−C拮抗剤と抗腫瘍性組成物との複合薬であって、
抗腫瘍性組成物は、ハイブリドーマATCC HB 10709によって産生されたモノクローナルVEGF−A抗体A4.6.1と同じエピトープに結合するVEGF−A抗体を含むヒトの対象中のがんを治療する複合薬。 - VEGF−C拮抗剤は、VEGF−C抗体、VEGF−C変異体、VEGFR−3抗体、VEGF−Cに特異的な受容体、VEGFR−3受容体、VEGF−CまたはVEGF−Cに特異的な受容体をブロック可能なアプタマー、VEGFR−3チロシンキナーゼの低分子量阻害剤から選択され、
任意成分として、VEGF−C拮抗剤は、VEGF−C抗体であり、
任意成分として、VEGF−C拮抗剤は、ハイブリドーマATCC PTA−4095により生成されたVEGF−Cのモノクローナル抗体69D09と同じエピトープに結合するVEGF−C抗体である請求項1に記載の複合薬。 - VEGF−A抗体は、ヒト抗体またはヒト化抗体である請求項1または2に記載の複合薬。
- VEGF−A抗体はベバシズマブである請求項3に記載の複合薬。
- 抗腫瘍性組成物は、化学療法剤をさらに含む請求項1〜4のいずれか1項に記載の複合薬。
- 化学療法剤は、ドセタキセル、5−フルオロウラシル(5−FU)、テモゾロマイド(TMZ)、ゲムシタビン、オキサリプラチン、パクリタキセル、カルボプラチンおよびイリノテカンから構成される群から選択される請求項5に記載の複合薬。
- 治療されるがん用の標準治療剤を含む請求項1〜6のいずれか1項に記載の複合薬。
- がんは、転移性、ステージIIIまたはステージIVである請求項1〜7のいずれか1項に記載の複合薬。
- がんは、肺がん、気管支がん、結腸直腸がん、前立腺がん、膵臓がん、肝臓がん、食道がん、膀胱腺(urinary)がん、膀胱(bladder)がん、腎臓がん、乳がん、卵巣がんおよび脳腫瘍、膠芽細胞腫、および非ホジキンリンパ腫から選択される請求項1〜8のいずれか1項に記載の複合薬。
- がんは、再発性であって、任意的に局所的に再発性である請求項1〜9のいずれか1項に記載の複合薬。
- 対象は、以前治療を受けていない請求項1〜10のいずれか1項に記載の複合薬。
- がんは、抵抗性を有し、任意的にVEGF−A拮抗剤に対して抵抗性を有する請求項1〜11のいずれか1項に記載の複合薬。
- 任意の順序にて連続的に投与される請求項1〜12のいずれか1項に記載の複合薬。
- ヒトの対象中のがんを治療する際に使用されるVEGF−C拮抗剤を含み、当該VEGF−C拮抗剤は、抗腫瘍性組成物と併用して対象に投与するためのものであって、
抗腫瘍性組成物は、ハイブリドーマATCC HB 10709によって産生されたモノクローナルVEGF−A抗体A4.6.1と同じエピトープに結合するVEGF−A抗体を含むキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32460810P | 2010-04-15 | 2010-04-15 | |
US61/324,608 | 2010-04-15 | ||
PCT/AU2011/000386 WO2011127519A1 (en) | 2010-04-15 | 2011-04-05 | Combination treatment with vegf-c antagonists |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015185027A Division JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Vegf−c拮抗剤を用いた併用治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013523843A JP2013523843A (ja) | 2013-06-17 |
JP2013523843A5 true JP2013523843A5 (ja) | 2014-05-22 |
Family
ID=44798165
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013504061A Pending JP2013523843A (ja) | 2010-04-15 | 2011-04-05 | Vegf−c拮抗剤を用いた併用治療 |
JP2015185027A Withdrawn JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Vegf−c拮抗剤を用いた併用治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015185027A Withdrawn JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Vegf−c拮抗剤を用いた併用治療 |
Country Status (5)
Country | Link |
---|---|
US (3) | US20120207671A1 (ja) |
EP (1) | EP2558122A4 (ja) |
JP (2) | JP2013523843A (ja) |
CA (1) | CA2796205A1 (ja) |
WO (1) | WO2011127519A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140123558A (ko) * | 2012-02-02 | 2014-10-22 | 악셀레론 파마 인코포레이티드 | Alk1 길항제 및 신세포 암종 치료에서의 그의 용도 |
US20140057851A1 (en) * | 2012-08-24 | 2014-02-27 | WKD Holding Oy | Anti-Angiogenic Gene Therapy With Soluble VEGF Receptors -1, -2 and -3 Together With Paclitaxel Prolongs Survival Of Mice With Human Ovarian Carcinoma |
WO2014043480A1 (en) * | 2012-09-13 | 2014-03-20 | Crystal Ronald G | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
US10561707B2 (en) | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
KR102131370B1 (ko) | 2013-10-18 | 2020-07-08 | 삼성전자주식회사 | Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도 |
MA42844A (fr) * | 2015-09-17 | 2018-07-25 | Immunogen Inc | Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1 |
WO2017130194A1 (en) * | 2016-01-25 | 2017-08-03 | Rappaport Family Institute For Research In The Medical Sciences | Semaphorin 3c variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
EP3272771A1 (en) * | 2016-07-22 | 2018-01-24 | Centre National De La Recherche Scientifique | Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation |
EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
CN110430896A (zh) | 2017-02-14 | 2019-11-08 | 伊索弗尔医药公司 | 用于增加血浆2′-脱氧尿苷(dUrd)和胸苷酸合成酶抑制的方法 |
WO2018189403A1 (en) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
WO2022238459A1 (en) * | 2021-05-11 | 2022-11-17 | Centre National De La Recherche Scientifique (Cnrs) | New humanized anti-vegfc antibodies and uses thereof |
AU2022327397A1 (en) * | 2021-08-13 | 2024-03-14 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-vegf a and -vegf c bispecific antibody and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6824777B1 (en) * | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US7208582B2 (en) * | 2001-04-13 | 2007-04-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
HUE058817T2 (hu) * | 2004-09-03 | 2022-09-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
EP2077845A2 (en) * | 2006-10-27 | 2009-07-15 | Janssen Pharmaceutica N.V. | Macrocyclic quinazoline derivatives as vegfr3 inhibitors |
US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
US9011861B2 (en) * | 2010-02-25 | 2015-04-21 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
-
2011
- 2011-04-05 WO PCT/AU2011/000386 patent/WO2011127519A1/en active Application Filing
- 2011-04-05 JP JP2013504061A patent/JP2013523843A/ja active Pending
- 2011-04-05 US US13/501,600 patent/US20120207671A1/en not_active Abandoned
- 2011-04-05 CA CA2796205A patent/CA2796205A1/en not_active Abandoned
- 2011-04-05 EP EP11768266.6A patent/EP2558122A4/en not_active Withdrawn
-
2013
- 2013-08-29 US US14/013,203 patent/US20130344065A1/en not_active Abandoned
-
2015
- 2015-04-27 US US14/697,175 patent/US20150224191A1/en not_active Abandoned
- 2015-09-18 JP JP2015185027A patent/JP2016040269A/ja not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013523843A5 (ja) | ||
Walker et al. | Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? | |
Fornaro et al. | FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO) | |
JP2018508512A5 (ja) | ||
De Gramont et al. | Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer | |
JP2017533912A5 (ja) | ||
Mok et al. | Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial | |
JP2008531576A5 (ja) | ||
JP2007526455A5 (ja) | ||
JP2018536632A5 (ja) | B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子 | |
JP2011512332A5 (ja) | ||
JP2017506264A5 (ja) | ||
HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
JP2018516911A5 (ja) | ||
JP2016520528A5 (ja) | ||
RU2020102237A (ru) | Связывающие il-1-бета антитела для применения в лечении рака | |
MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
Hegde et al. | Systemic and targeted therapy for advanced colon cancer | |
RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
JP2015532292A5 (ja) | ||
JP2014034576A5 (ja) | ||
JP2020524694A5 (ja) | ||
RU2015143437A (ru) | Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака | |
JP2013166763A5 (ja) | ||
JP2013520442A5 (ja) |